← Back to Search
Radiopharmaceutical
Mechanisms of Resistance to PSMA Radioligand Therapy
New York, NY
N/A
Recruiting
Led By Thomas Hope, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group
Summary
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
See full description
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean whole body tumor absorbed dose (WB Dose) across all metastatic lesions
Median PORTOS score
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants undergoing 177Lu-PSMA-617 treatmentExperimental Treatment3 Interventions
Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood Draw
2014
Completed Phase 4
~2350
Tumor Biopsy
2017
Completed Phase 2
~400
Single-photon emission computed tomography
2010
N/A
~50
Find a Location
Closest Location:University of California, Los Angeles· Los Angeles, CA· 1181 miles
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,625 Previous Clinical Trials
19,027,460 Total Patients Enrolled
51 Trials studying Prostate Cancer
17,502 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
14,056 Previous Clinical Trials
41,149,346 Total Patients Enrolled
518 Trials studying Prostate Cancer
333,826 Patients Enrolled for Prostate Cancer
Prostate Cancer FoundationOTHER
51 Previous Clinical Trials
2,903 Total Patients Enrolled
27 Trials studying Prostate Cancer
1,835 Patients Enrolled for Prostate Cancer
Thomas Hope, MDPrincipal InvestigatorUniversity of California, San Francisco
11 Previous Clinical Trials
2,123 Total Patients Enrolled
5 Trials studying Prostate Cancer
1,515 Patients Enrolled for Prostate Cancer